← Back to patent-cliff list
D-0120-NA
Tier C — Watch / tradeD-0120-NA
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：URAT1
Indications (approved)：Gout, Hyperuricaemia
Regional status
US
Phase II
2023-04-17
EU
-
China
Phase II
2019-04-18
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of D-0120-NA?
Approved indications include: Gout, Hyperuricaemia.
When does the D-0120-NA patent expire?
No public expiry year is available for D-0120-NA yet; this page updates once verified.
How do I get a quote for D-0120-NA intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08